1. International Agency for Research on Cancer. World cancer report 2014. Available from: [Last accessed on 17 Oct 2018].

2. Gamboa A, Lin Q, Jin P, Zhou Y, Liu Q, et al. The descriptive epidemiology of gastrointestinal malignancies. In: Cai Q, El-Rayes BF, Hao J, editors. Gastrointestinal malignancies: new innovative diagnostics and treatment. New Jersey: World Scientific; 2015. pp. 1-40.

3. Lung MS, Trainer AH, Campbell I, Lipton L. Familial colorectal cancer. Intern Med J 2015;45:482-91.

4. Wells K, Wise PE. Hereditary colorectal cancer syndromes. Surg Clin North Am 2017;97:605-25.

5. Lorans M, Dow E, Macrae FA, Winship IM, Buchanan DD. Update on hereditary colorectal cancer: improving the clinical utility of multigene panel testing. Clin Colorectal Cancer 2018;17:e293-305.

6. Lynch HT, Lynch J. Lynch syndrome: genetics, natural history, genetic counseling, and prevention. J Clin Oncol 2000;18:19S-31S.

7. Planck M1, Rambech E, Möslein G, Müller W, Olsson H, et al. High frequency of microsatellite instability and loss of mismatch-repair protein expression in patients with double primary tumors of the endometrium and colorectum. Cancer 2002;94:2502-10.

8. Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mutat 1997;10:89-99.

9. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, et al. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003;27:1407-17.

10. Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-9.

11. Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the international collaborative group on HNPCC. Gastroenterology 1999;116:1453-6.

12. Rodriguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, et al. A national cancer institute workshop on hereditary nonpolyposis colorectal cancer syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997;89:1758-62.

13. Müller W, Burgart LJ, Krause-Paulus R, Thibodeau SN, Almeida M, et al. The reliability of immunohistochemistry as a prescreening method for the diagnosis of hereditary nonpolyposis colorectal cancer (HNPCC)--results of an international collaborative study. Fam Cancer 2001;1:87-92.

14. Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, et al. Assessment of tumor sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol 2018;4:806-13.

15. Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 2013;62:812-23.

16. Rau B, Angele M, Gonzalez-Moreno S, Kähler G, Langelotz C, et al. Gender-specific aspects in gastrointestinal medicine and surgery. Viszeralmedizin 2014;30:133-5.

17. Möslein G, Ohmann C, Wenzel M. Prophylactic surgery for hereditary non-polyposis colorectal cancer. Chirurg 2005;76:1135-44. (in German)

18. Schneider R, Fürst A, Möslein G. Gender-specific aspects of Lynch syndrome--an update. Z Gastroenterol 2015;53:789-93. (in German)

19. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009;11:354-64.

20. Heald RJ, Moran BJ, Ryall RD, Sexton R, MacFarlane JK. Rectal cancer: the Basingstoke experience of total mesorectal excision, 1978-1997. Arch Surg 1998;133:894-9.

21. Hazebroek EJ; Color Study Group. COLOR: a randomized clinical trial comparing laparoscopic and open resection for colon cancer. Surg Endosc 2002;16:949-53.

22. Kneist W, Hanke L, Kauff DW, Lang H. Surgeons’ assessment of internal anal sphincter nerve supply during TaTME - inbetween expectations and reality. Minim Invasive Ther Allied Technol 2016;25:241-6.

23. Kneist W, Wachter N, Paschold M, Kauff DW, Rink AD, et al. Midterm functional results of taTME with neuromapping for low rectal cancer. Tech Coloproctol 2016;20:41-9.

24. Aretz S, Uhlhaas S, Sun Y, Pagenstecher C, Mangold E, et al. Familial adenomatous polyposis: aberrant splicing due to missense or silent mutations in the APC gene. Hum Mutat 2004;24:370-80.

25. Bisgaard ML, Fenger K, Bülow S, Niebuhr E, Mohr J. Familial adenomatous polyposis (FAP): frequency, penetrance, and mutation rate. Hum mutat 1994;3:121-5.

26. Knudsen AL, Bülow S, Tomlinson I, Möslein G, Heinimann K, et al. Attenuated familial adenomatous polyposis: results from an international collaborative study. Colorectal Dis 2010;12:e243-9.

27. Bülow S. Diagnosis of familial adenomatous polyposis. World J Surg 1991;15:41-6.

28. Dörner J, Fallahpour MT, Möslein G. Surgical management of hereditary colorectal cancer syndromes. In: Valle L, Gruber S, Capellá G, editors. Hereditary colorectal cancer. Cham: Springer; 2018. pp. 327-47.

29. De Cosse JJ, Bülow S, Neale K, Järvinen H, Alm T, et al. Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle polyposis group. Br J Surg 1992;79:1372-5.

30. Lynch HT, Smyrk T, McGinn T, Lanspa S, Cavalieri J, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995;76:2427-33.

31. Knudsen AL, Bisgaard ML, Bülow S. Attenuated familial adenomatous polyposis (AFAP): a review of the literature. Fam cancer 2003;2:43-55.

32. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008;15:2439-50.

33. Traboulsi EI, Krush AJ, Gardner EJ, Booker SV, Offerhaus GJ, et al. Prevalence and importance of pigmented ocular fundus lesions in Gardner’s syndrome. N Engl J Med 1987;316:661-7.

34. Naylor EW, Gardner EJ, Richards RC. Desmoid tumors and mesenteric fibromatosis in Gardner’s syndrome: report of kindred 109. Arch Surg 1979;114:1181-5.

35. Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008;57:704-13.

36. Lynch PM, Morris JS, Wen S, Advani SM, Ross W, et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 2016;84:115-25.

37. Ambe PC, Möslein G. Ileoanal pouch. Coloproctology 2018;40:130-5.

38. Remzi FH, Fazio VW, Delaney CP, Preen M, Ormsby A, et al. Dysplasia of the anal transitional zone after ileal pouch-anal anastomosis: results of prospective evaluation after a minimum of ten years. Dis Colon Rectum 2003;46:6-13.

39. Carne PW, Pemberton JH. Technical aspects of ileoanal pouch surgery. Clin Colon Rectal Surg 2004;17:35-41.

40. Van Duijvendijk P, Slors JF, Taat CW, Oosterveld P, Sprangers MA, et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2000;87:590-6.

41. DE Marchis ML, Tonelli F, Quaresmini D, Lovero D, Della-Morte D, et al. Desmoid tumors in familial adenomatous polyposis. Anticancer Res 2017;37:3357-66.

42. Ambe PC, Zirngibl H, Möslein G. Routine virtual ileostomy following restorative proctocolectomy for familial adenomatous polyposis. World J Surg 2018;42:1867-71.

43. Monson JR, Arsalanizadeh R. Transanal total mesorectal excision (TaTME) and quality of rectal cancer surgery: do we really know? Ann Surg 2017;266:e88-9.

44. Ambe PC, Zirngibl H, Möslein G. Initial experience with taTME in patients undergoing laparoscopic restorative proctocolectomy for familial adenomatous polyposis. Tech Coloproctol 2017;21:971-4.

45. Reilly WT, Pemberton JH, Wolff BG, Nivatvongs S, Devine RM, et al. Randomized prospective trial comparing ileal pouch-anal anastomosis performed by excising the anal mucosa to ileal pouch-anal anastomosis performed by preserving the anal mucosa. Ann Surg 1997;225:666-76.

46. Rullier E, Laurent C, Garrelon JL, Michel P, Saric J, et al. Risk factors for anastomotic leakage after resection of rectal cancer. Br J Surg 1998;85:355-8.

47. Aziz O, Albeyatti A, Derias M, Varsani N, Ashrafian H, et al. PTU-202 A case-controlled study demonstrating that changes associated with rectal anastomotic leakage are detectable within 48 hours of surgery. Gut 2015;64:A152.

48. Al-Tassan N, Chmiel NH, Maynard J, Fleming N, Livingston AL, et al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet 2002;30:227-32.

49. Mazzei F, Viel A, Bignami M. Role of MUTYH in human cancer. Mutat Res 2013;743-744:33-43.

50. Nielsen M, Joerink-van de Beld MC, Jones N, Vogt S, Tops CM, et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 2009;136:471-6.

51. Nieuwenhuis MH, Vogt S, Jones N, Nielsen M, Hes FJ, et al. Evidence for accelerated colorectal adenoma--carcinoma progression in MUTYH-associated polyposis? Gut 2012;61:734-8.

52. De Rosa M, Galatola M, Quaglietta L, Miele E, De Palma G, et al. Alu-mediated genomic deletion of the serine/threonine protein kinase 11 (STK11) gene in Peutz-Jeghers syndrome. Gastroenterology 2010;138:2558-60.

53. Howe JR, Roth S, Ringold JC, Summers RW, Järvinen HJ, et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998;280:1086-8.

54. Howe JR, Bair JL, Sayed MG, Anderson ME, Mitros FA, et al. Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis. Nat Genet 2001;28:184-7.

55. Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008;27:5387-97.

56. Utsunomiya J, Gocho H, Miyanaga T, Hamaguchi E, Kashimure A. Peutz-Jeghers syndrome: its natural course and management. Johns Hopkins Med J 1975;136:71-82.

57. Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010;59:975-86.

58. Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits; a syndrome of diagnostic significance. N Engl J Med 1949;241:993.

59. Giardiello FM, Trimbath JD. Peutz-Jeghers syndrome and management recommendations. Clin Gastroenterol Hepatol 2006;4:408-15.

60. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006;12:3209-15.

61. Lefevre H, Bouvattier C, Lahlou N, Adamsbaum C, Bougnères P, et al. Prepubertal gynecomastia in Peutz-Jeghers syndrome: incomplete penetrance in a familial case and management with an aromatase inhibitor. Eur J Endocrinol 2006;154:221-7.

62. Palles C, Cazier JB, Howarth KM, Domingo E, Jones AM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 2013;45:136-44.

63. Spier I, Holzapfel S, Altmüller J, Zhao B, Horpaopan S, et al. Frequency and phenotypic spectrum of germline mutations in POLE and seven other polymerase genes in 266 patients with colorectal adenomas and carcinomas. Int J Cancer 2015;137:320-31.

64. Valle L, Hernández-Illán E, Bellido F, Aiza G, Castillejo A, et al. New insights into POLE and POLD1 germline mutations in familial colorectal cancer and polyposis. Hum Mol Genet 2014;23:3506-12.

65. Hahn MM, Vreede L, Bemelmans SA, van der Looij E, van Kessel AG, et al. Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with early-onset colorectal cancer. Genes Chromosomes Cancer 2016;55:855-63.

66. Bellido F, Pineda M, Aiza G, Valdés-Mas R, Navarro M, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med 2016;18:325-32.

67. Buchanan DD, Stewart JR, Clendenning M, Rosty C, Mahmood K, et al. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1. Genet Med 2018;20:890-5.

68. Weren RD, Ligtenberg MJ, Kets CM, de Voer RM, Verwiel ET, et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 2015;47:668-71.

69. Broderick P, Dobbins SE, Chubb D, Kinnersley B, Dunlop MG, et al. Validation of recently proposed colorectal cancer susceptibility gene variants in an analysis of families and patients-a systematic review. Gastroenterology 2017;152:75-7.

70. Chubb D, Broderick P, Dobbins SE, Frampton M, Kinnersley B, et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun 2016;7:11883.

71. Adam R, Spier I, Zhao B, Kloth M, Marquez J, et al. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 2016;99:337-51.

Mini-invasive Surgery
ISSN 2574-1225 (Online)
Follow Us


All published articles are preserved here permanently:


All published articles are preserved here permanently: